A study has revealed that the microbiome could impact COVID-19 severity and may be implicated in persisting inflammatory symptoms.
List view / Grid view
Filter the results
Using cryo-electron microscopy, researchers have observed the structure of a diarrhoea enteric adenovirus to see how it can survive the stomach.
Researchers have identified microbes that could affect the way a person metabolises glucose and lipids, leading to a potential treatment for type 2 diabetes.
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
Several new advances have been made in the field of drug discovery for diabetes – here, three of the most recent have been rounded up.
Researchers have shown that CRISPR-Cas3 can successfully attack C. difficile in vitro and in mice, by causing DNA damage to the pathogen.
Research indicates both S. aureus and S. epidermidis exacerbate skin inflammation, so could be targeted to help treat Netherton syndrome.
Research has shown that leaky gut, the break down of gut lining junctions, could be targeted to reduce inflammation using metformin using an organoid model.
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
A study of published papers has revealed the importance of research into how the microbiome affects the development of melanoma.
A new study into why neurons in the gut die and how the immune system protects them could lead to better treatments for IBS that work by boosting polyamine production.
Research has found that bile acids, converted by gut microbes, act as inflammatory regulators in IBD by modulating the differentiation of T cells in the gut.
Researchers have found that supplementing drinking water with short chain fatty acids helped mice to recover from stroke by increasing microglia activity.
A study in mice has shown that immunisation against bacterial flagellin could lead to protection from chronic inflammatory diseases.
In a pre-clinical model of multiple sclerosis, orally treating susceptible mice with a microRNA from the diseased gut has prevented the disease.